Showing 6121-6130 of 21464 results for "".
- Exploring Degradation and Metabolic Effects in Modern Pharmacotherapyhttps://reachmd.com/news/exploring-degradation-and-metabolic-effects-in-modern-pharmacotherapy/2483113/As pharmacotherapy evolves, addressing the clinical challenge of assessing treatment stability and systemic impact becomes increasingly crucial. Biosimilars, pivotal in modern treatment strategies, are continually scrutinized under thermal stress, influencing therapeutic approaches
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://reachmd.com/news/amarte-relaunches-dermatologist-formulated-ultra-veil-daily-spf-40/2483103/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release
- Prognostic and Therapeutic Biomarkers in Cancer: A Pathway to Personalized Treatmenthttps://reachmd.com/news/prognostic-and-therapeutic-biomarkers-in-cancer-a-pathway-to-personalized-treatment/2483084/Clinicians are weighing the promise of biomarker-driven precision against the practical realities of integrating these signals into everyday care. Amid the push to translate laboratory signals into care, the integration of immune–metabolic models into hepatocellular
- Advancements in Liver Transplant Anesthesia: Enhanced Recovery Protocolshttps://reachmd.com/news/advancements-in-liver-transplant-anesthesia-enhanced-recovery-protocols/2483092/Liver transplant procedures are currently witnessing a transformation driven by enhanced recovery protocols in anesthesia. Many centers are adapting ERAS-style perioperative pathways for liver transplantation, aligned with emerging consensus statements, though implementation remains center-
- Uncovering Dermatology's Spectrum: Lebrikizumab's Promise in Skin of Colorhttps://reachmd.com/news/uncovering-dermatologys-spectrum-lebrikizumabs-promise-in-skin-of-color/2483099/Atopic dermatitis (AD) represents a common dermatological challenge, particularly in skin of color, where its presentation and treatment efficacy can diverge significantly, a nuance acknowledged in major dermatology guidelines and consensus statements. Addressing this evidence gap re
- Enliven Therapeutics' Pioneering SOHO 2025 Presentations: New Frontiers in Hematologyhttps://reachmd.com/news/enliven-therapeutics-pioneering-soho-2025-presentations-new-frontiers-in-hematology/2483101/With early findings from the ENABLE Phase 1a/1b trial presented at SOHO 2025, Enliven Therapeutics reports preliminary signals that may help address treatment resistance in chronic myeloid leukemia. Enliven Therapeutics' early-stage investigation unfolds as the ENABLE Phase 1a/1b tri
- Deciphering Subaortic Stenosis: Navigating Diagnostic Challenges and Anatomical Complexitieshttps://reachmd.com/news/deciphering-subaortic-stenosis-navigating-diagnostic-challenges-and-anatomical-complexities/2483080/Subaortic stenosis, an often under-recognized cause of narrowing below the aortic valve (left ventricular outflow tract), poses significant diagnostic challenges due to its diverse anatomical variations. Clinicians should employ precise cardiac imaging to guide diagnosis and intervention de
- The Potential Role of Omega-3 Fatty Acids in Preventing Nearsightedness in Childrenhttps://reachmd.com/news/the-potential-role-of-omega-3-fatty-acids-in-preventing-nearsightedness-in-children/2483098/Nearsightedness continues its global rise in children, prompting researchers to explore whether omega-3 fatty acids could play a supportive role. The prevalence of nearsightedness, also known as myopia, in children is climbing worldwide, signaling a pressing need for effective preven
- Breaking New Ground: Novartis’ Monoclonal Antibody for Sjögren’s Syndromehttps://reachmd.com/news/breaking-new-ground-novartis-monoclonal-antibody-for-sjogrens-syndrome/2483100/Novartis’ groundbreaking monoclonal antibody is reshaping the discussion around Sjögren’s syndrome treatment by targeting core immunologic drivers while new clinical data emerge.
- Revolutionizing Bronchiectasis Care: The Brensocatib Breakthroughhttps://reachmd.com/news/revolutionizing-bronchiectasis-care-the-brensocatib-breakthrough/2483069/The potential introduction of brensocatib into care for non–cystic fibrosis bronchiectasis marks a notable moment in a field with substantial unmet need, but its regulatory status remains under review and should be described as investigational rather than approved.